Cellestia Enters Clinical Development for its Lead Compound CB-103
On August 11th Cellestia received full approval of its first-in-human Phase I – IIa clinical study with CB-103. See our Press Release.
Management Team and Scientific Advisory Board extension
Gaudenz von Capeller has been appointed Chief Financial Officer. Professor Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research (ISREC), has been appointed as Chairman of the Scientific Advisory Board. See our Press Release.